Keenova Expands Terlipressin Data for Liver Transplant-Ineligible HRS-AKI Patients

  • Keenova presented new exploratory analysis of TERLIVAZ® (terlipressin) for HRS-AKI patients ineligible for liver transplant at the American College of Gastroenterology Annual Meeting on October 12, 2026.
  • The analysis expands clinical evidence for terlipressin use in a previously understudied patient population.
  • TERLIVAZ remains the only FDA-approved therapy for HRS-AKI, with specific safety warnings about respiratory failure risks.
  • HRS-AKI inpatient diagnoses in the U.S. increased from 42,930 to 63,381 annually between 2018-2023.

Keenova's presentation addresses a critical gap in HRS-AKI treatment for patients who cannot undergo liver transplantation, a population that has been growing rapidly. The company is positioning TERLIVAZ as the standard of care in this niche, despite its significant safety profile challenges. This strategic move comes as rare disease therapeutics continue to gain focus in the biopharmaceutical sector, with increasing attention on specialized treatments for liver and kidney complications.

Market Expansion
How Keenova will leverage this data to expand TERLIVAZ's addressable patient population beyond liver transplant candidates.
Competitive Positioning
Whether this analysis will strengthen TERLIVAZ's market position as the only FDA-approved HRS-AKI treatment.
Regulatory Scrutiny
The pace at which FDA may require additional safety data given TERLIVAZ's serious respiratory failure warnings.